

An overview of precision oncology basket and umbrella

Ca-A Cancer Journal for Clinicians

70, 125-137

DOI: [10.3322/caac.21600](https://doi.org/10.3322/caac.21600)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE, 2020, 15, e0237802.	1.1	223
2	What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report. Cancer, 2020, 126, 5022-5029.	2.0	9
3	Emerging role of long noncoding RNA-encoded micropeptides in cancer. Cancer Cell International, 2020, 20, 506.	1.8	41
4	Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy. ACS Combinatorial Science, 2020, 22, 669-700.	3.8	65
5	Tyrosine Kinase Receptors in Oncology. International Journal of Molecular Sciences, 2020, 21, 8529.	1.8	46
6	Is it accurate to classify ALS as a neuromuscular disorder?. Expert Review of Neurotherapeutics, 2020, 20, 895-906.	1.4	12
7	The emerging role of precision medicine in the treatment of ovarian cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 283-297.	0.4	3
8	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 557-588.	8.2	1,155
9	Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to. Annals of Hematology, 2020, 99, 1161-1176.	0.8	9
10	The efficacy of off-label IL-5-modulating treatment in rare eosinophil-mediated diseases. Allergy International, 2021, 70, 266-268.	1.4	7
11	A Perspective of Epigenetic Regulation in Radiotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 624312.	1.8	19
12	The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. Cancer Treatment Reviews, 2021, 94, 102169.	3.4	14
13	Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine. Pharmacoeconomics, 2021, 39, 771-788.	1.7	24
14	Precision oncology in metastatic colorectal cancer – from biology to medicine. Nature Reviews Clinical Oncology, 2021, 18, 506-525.	12.5	113
16	Randomised trials at the level of the individual. The Lancet Global Health, 2021, 9, e691-e700.	2.9	11
17	Precision Oncology. Advances in Oncology, 2021, 1, 97-112.	0.1	0
18	Cardiac-sparing radiotherapy for locally advanced non-small cell lung cancer. Radiation Oncology, 2021, 16, 95.	1.2	5
20	Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institution. Cancer Reports, 2021, , e1465.	0.6	1

#	ARTICLE	IF	CITATIONS
21	Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine. <i>Journal of Genetics and Genomics</i> , 2021, 48, 540-551.	1.7	19
22	An Overview of Phase 2 Clinical Trial Designs. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 22-29.	0.4	11
23	Impact of Precision Medicine on Clinical Outcomes: A Single-Institution Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 659113.	1.3	4
24	Primary signet ring cell histology does not portend worse survival for early stage lung cancer following lobectomy. <i>Asian Cardiovascular and Thoracic Annals</i> , 2021, , 021849232110459.	0.2	1
25	Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives. <i>Nucleic Acid Therapeutics</i> , 2022, 32, 83-94.	2.0	35
26	Toward the Next Generation of High-Grade Glioma Clinical Trials in the Era of Precision Medicine. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 410-415.	1.0	5
27	Genomic landscape and tumor mutation burden analysis of Chinese patients with sarcomatoid carcinoma of the head and neck. <i>Oral Oncology</i> , 2021, 121, 105436.	0.8	3
28	Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment. <i>Lancet Oncology, The</i> , 2021, 22, e430-e434.	5.1	24
29	Why Immunotherapy Fails in Multiple Myeloma. <i>Hemato</i> , 2021, 2, 1-42.	0.2	5
30	Triple-negative breast cancer therapy: Current and future perspectives (Review). <i>International Journal of Oncology</i> , 2020, 57, 1245-1261.	1.4	196
31	Liquid Biopsies for Molecular Biology-Based Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11267.	1.8	4
32	Prognostic Gene Signature for Squamous Cell Carcinoma with a Higher Risk for Treatment Failure and Accelerated MEK-ERK Pathway Activity. <i>Cancers</i> , 2021, 13, 5182.	1.7	5
33	Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1611-1624.	1.5	7
35	BuqiTongluo Granule for Ischemic Stroke, Stable Angina Pectoris, Diabetic Peripheral Neuropathy with Qi Deficiency and Blood Stasis Syndrome: Rationale and Novel Basket Design. <i>Frontiers in Pharmacology</i> , 2021, 12, 764669.	1.6	6
36	Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers. <i>Frontiers in Public Health</i> , 2021, 9, 754482.	1.3	2
37	Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives. <i>Cancers</i> , 2021, 13, 5660.	1.7	16
38	It is time to move to alternative clinical trial designs: Reconsidering the holy grail of trial methodology. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103426.	0.9	0
39	Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness. <i>Frontiers in Medicine</i> , 2021, 8, 818647.	1.2	7

#	ARTICLE	IF	CITATIONS
40	High-grade glioma therapy: adding flexibility in trial design to improve patient outcomes. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 275-287.	1.1	3
41	Cancer gene mutation frequencies for the U.S. population. <i>Nature Communications</i> , 2021, 12, 5961.	5.8	78
42	Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects. <i>Nature Communications</i> , 2022, 13, 873.	5.8	13
43	Defining a Core Data Set for the Economic Evaluation of Precision Oncology. <i>Value in Health</i> , 2022, 25, 1371-1380.	0.1	6
44	Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3012.	1.8	6
45	Therapeutic impact and routine application of next-generation sequencing: A single institute study. <i>Biomedical Reports</i> , 2022, 16, 33.	0.9	0
46	Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. <i>PLoS ONE</i> , 2022, 17, e0264138.	1.1	100
47	Role of Image-Guided Percutaneous Needle Biopsy in the Age of Precision Medicine. <i>Current Oncology Reports</i> , 2022, 24, 1035-1044.	1.8	2
48	Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study. <i>BMC Medical Research Methodology</i> , 2021, 21, 282.	1.4	0
49	Precision diagnostics in cancer: Predict, prevent, and personalize. <i>Progress in Molecular Biology and Translational Science</i> , 2022, , 39-56.	0.9	1
50	Study designs for clinical trials applied to personalised medicine: a scoping review. <i>BMJ Open</i> , 2022, 12, e052926.	0.8	11
51	Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid Tumors. <i>Cancers</i> , 2022, 14, 2457.	1.7	8
52	Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing. <i>British Journal of Cancer</i> , 0, , .	2.9	2
53	Treatment of biliary tract carcinoma over the last 30 years. <i>BioScience Trends</i> , 2022, 16, 189-197.	1.1	2
54	Approach for reporting master protocol study designs on ClinicalTrials.gov: qualitative analysis. <i>BMJ</i> , The, 0, , e067745.	3.0	1
55	A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
56	Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	4
57	Clinical and population-based study design considerations to accelerate the investigation of new antiretrovirals during pregnancy. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	6

#	ARTICLE	IF	CITATIONS
59	Translational cancer research in India: Challenges and promises. <i>Journal of Cancer Research and Therapeutics</i> , 2023, 19, 526-529.	0.3	1
60	Identification of Fusion Genes and Targets for Genetically Matched Therapies in a Large Cohort of Salivary Gland Cancer Patients. <i>Cancers</i> , 2022, 14, 4156.	1.7	5
61	Clinical trial design in the era of precision medicine. <i>Genome Medicine</i> , 2022, 14, .	3.6	68
62	Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment. <i>Genome Medicine</i> , 2022, 14, .	3.6	3
63	Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. <i>Trials</i> , 2022, 23, .	0.7	4
64	Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). <i>Clinical Cancer Research</i> , 2023, 29, 401-409.	3.2	4
65	Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late?. <i>Cytotherapy</i> , 2023, 25, 341-352.	0.3	11
66	Design and analysis of umbrella trials: Where do we stand?. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
67	Signaling pathways and therapeutic interventions in gastric cancer. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	54
68	Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective. <i>Cancers</i> , 2022, 14, 4828.	1.7	11
69	A perspective on oligonucleotide therapy: Approaches to patient customization. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	23
70	Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study. <i>Cancer Medicine</i> , 2023, 12, 6170-6181.	1.3	3
71	<i>WT1</i> and <i>DNMT3A</i> play essential roles in the growth of certain patient AML cells in mice. <i>Blood</i> , 0, , .	0.6	0
72	A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target. <i>European Journal of Cancer</i> , 2023, 178, 227-233.	1.3	3
73	Current Status of Natural Products/siRNA Co-Delivery for Cancer Therapy. <i>ChemistrySelect</i> , 2022, 7, .	0.7	0
74	Pan-cancer analyses reveal IGSF10 as an immunological and prognostic biomarker. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
75	Challenges and Solutions for the Benefit Assessment of Tumor-Agnostic Therapies in Germany. <i>Value in Health</i> , 2023, 26, 854-864.	0.1	2
77	First-line crizotinib therapy is effective for a novel SEC31A-anaplastic lymphoma kinase fusion in a patient with stage IV lung adenocarcinoma: a case report and literature reviews. <i>Anti-Cancer Drugs</i> , 2023, 34, 294-301.	0.7	0

#	ARTICLE	IF	CITATIONS
78	Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health. <i>BMJ Evidence-Based Medicine</i> , 2024, 29, 1-5.	1.7	11
79	RAPID framework for improved access to precision oncology for lethal disease: Results from a modified multi-round delphi study. , 0, 3, .		1
80	Randomized controlled trials and alternative study designs in surgical oncology. <i>European Journal of Surgical Oncology</i> , 2023, 49, 1331-1340.	0.5	1
81	Biologicals and small molecules as target-specific cancer chemotherapeutic agents. , 2023, , 615-646.		0
94	Inflammation across tissues: can shared cell biology help design smarter trials?. <i>Nature Reviews Rheumatology</i> , 2023, 19, 666-674.	3.5	2
100	Precision Nutrition and Cancer. , 2024, , 277-298.		1
112	Omics-based molecular classifications empowering in precision oncology. <i>Cellular Oncology (Dordrecht)</i> , 0, , .	2.1	0
114	Precision Medicine. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2024, , 257-280.	0.1	0
116	Pharmacogenomics and Precision Therapy in Prostate Cancer: Challenges and Perspectives. , 2024, , 335-377.		0